Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
Mohammad Habibullah, Khaleed Jemmieh, Amr Ouda, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
Reddemma Sandireddy, Suganya Sakthivel, Priyanka Gupta, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 26
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3694-3694
Open Access | Times Cited: 12
Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders
Laura Toma, Mariana Deleanu, Gabriela M. Sanda, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4162-4162
Open Access | Times Cited: 8
Effects of Sympathetic Denervation in Metabolism Regulation: A Novel Approach for the Treatment of MASLD?
Kyriakos Dimitriadis, Panagιotis Iliakis, Angeliki Vakka, et al.
Cardiology in Review (2025)
Closed Access | Times Cited: 1
AlphaFold-Based AI Docking Reveals AMPK/SIRT1-TFEB Pathway Modulation by Traditional Chinese Medicine in Metabolic-Associated Fatty Liver Disease
Lulu Zhang, Yi Zheng, Mingyan Shao, et al.
Pharmacological Research (2025), pp. 107617-107617
Open Access | Times Cited: 1
Hepatic HKDC1 deletion alleviates western diet-induced MASH in mice
Kai Xu, Irene Corona‐Avila, María Dolores Frutos, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 4, pp. 167746-167746
Open Access | Times Cited: 1
Roles of extracellular vesicles from different origins in metabolic-associated fatty liver disease: progress and perspectives
Xinyi Wang, Sônia Nair Báo, Qi An, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation
Ludovico Abenavoli, Maria Luisa Gambardella, Giuseppe Guido Maria Scarlata, et al.
Medicina (2024) Vol. 60, Iss. 4, pp. 563-563
Open Access | Times Cited: 7
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study
Carmen De, Rocco Spagnuolo, Angela Quirino, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5453-5453
Open Access | Times Cited: 5
Mitigating Effects of Tanacetum balsamita L. on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Rositsa Mihaylova, Reneta Gevrenova, А. В. Петрова, et al.
Plants (2024) Vol. 13, Iss. 15, pp. 2086-2086
Open Access | Times Cited: 4
The Management of Cardiometabolic Risk in MAFLD: Therapeutic Strategies to Modulate Deranged Metabolism and Cholesterol Levels
Alessandro Pezzoli, Ludovico Abenavoli, Marialaura Scarcella, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 387-387
Open Access
Enhancing poultry health and productivity through the liver-gut axis with integrated nutritional and immunological approaches: a mini-review
Felix Kwame Amevor, Victoria Anthony Uyanga, Liuting Wu, et al.
Frontiers in Physiology (2025) Vol. 16
Open Access
Regional insights into the relationship between metabolic associated steatotic liver disease and chronic kidney disease: a socioeconomic perspective on disease correlation
Jiang Bai, Lijuan Zhang, Mingyan Zhang, et al.
BMC Public Health (2025) Vol. 25, Iss. 1
Open Access
Protein kinase-mediated inhibition of autophagy by palmitic acid in hepatocytes
Yeon Jeong Kim, Jae Rim Lee, Minsoo Kim, et al.
European Journal of Pharmacology (2025), pp. 177528-177528
Closed Access
Nettle Leaf Water Extracts for Hepatoprotection: Insights into Bioactivity and Mitochondrial Function
Ruta Muceniece, Beatrise Luize Revina, Jorens Kviesis, et al.
Plants (2025) Vol. 14, Iss. 7, pp. 992-992
Open Access
Frequency and risk factors of metabolic associated fatty liver disease among medical students in Egypt
Mohamed Mahmoud Elhoseeny, Fatma Rageh, Samar M Rezk, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Duodenal mucosal ablation with irreversible electroporation reduces liver lipids in rats with non-alcoholic fatty liver disease
Jiawei Yu, Qi Zhao, Peixi Li, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 16
Closed Access
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue
Alberto Savino, Alessandro Loglio, Flavia Neri, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3871-3871
Open Access | Times Cited: 3
Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions
А.Е. Абатуров, Anna Nikulina
CHILD`S HEALTH (2024) Vol. 19, Iss. 2, pp. 107-116
Open Access | Times Cited: 2
Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic Target
Ilaria Milani, Michela Codini, Gloria Guarisco, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10795-10795
Open Access | Times Cited: 2
Structure characteristics of a novel pectic polysaccharide from Fructus Corni and its protective effect on alcoholic fatty liver
Hong-Xin Bai, Yulong Gao, Shuyao Wang, et al.
Carbohydrate Polymers (2024) Vol. 352, pp. 123153-123153
Closed Access | Times Cited: 1
Proinflammatory interleukins 2, 6 and tumor necrosis factor alpha in patients with hypertension and diabetes mellitus depending on the presence of metabolic-associated liver steatosis
О. М. Радченко, O.J. Komarytsia, M.O. Borovets, et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) (2024) Vol. 20, Iss. 3, pp. 200-203
Open Access
Clinical epidemiology of metabolic-associated fatty liver disease in overweight and obese children
O.O. Starets, T. M. Khimenko, I. Ye. Shapovalenko
CHILD`S HEALTH (2024) Vol. 19, Iss. 5, pp. 253-258
Open Access
Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer
Gianmarco Villano, Patrizia Pontisso
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top